A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab.
Patel M, Bauer T, Jimeno A, Wang D, LoRusso P, Do K, Stemmer S, Maurice-Dror C, Geva R, Zacharek S, Laino A, Sun J, Frederick J, Zhou H, Randolph W, Cohen P, Meehan R, Sullivan R. A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab. Journal Of Clinical Oncology 2020, 38: 3092-3092. DOI: 10.1200/jco.2020.38.15_suppl.3092.Peer-Reviewed Original ResearchSolid tumor patientsPro-inflammatory cytokinesIL-23IL-36γTumor shrinkageTumor patientsPost-treatment tumor biopsiesSquamous cell bladder carcinomaTumor-associated immune cellsDose-escalation partAdvanced solid malignanciesGrade 3/4 toxicitiesCytokine IL-22PD-L1 expressionPD-L1 levelsPD-L1 immunohistochemistryTime of presentationAnalysis of tumorsUninjected lesionsFirst doseIL-22Elevated IFNIL-6Immunomodulatory effectsBladder carcinoma